Annexin Pharmaceuticals AB
Stockholm Stock ExchangeTotal Valuation
Annexin Pharmaceuticals AB carries a market capitalization of 89.21M, placing it among publicly traded companies globally. Its enterprise value stands at 69.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 89.21M |
| Enterprise Value | 69.08M |
Share Statistics
Annexin Pharmaceuticals AB currently has 7.06M shares outstanding.
| Shares Outstanding | 7.06M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.23 |
| P/TBV Ratio | 6.03 |
| P/FCF Ratio | -2.22 |
| P/OCF Ratio | -2.21 |
Financial Position
Annexin Pharmaceuticals AB maintains a current ratio of 3.31, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.31 |
| Quick Ratio | 3.07 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -116.00 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Annexin Pharmaceuticals AB's stock has declined approximately -57.36301% over the past 52 weeks. The 50-day moving average sits at 13.66, while the 200-day moving average is 18.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | -57.36301% |
| 50-Day Moving Average | 13.66 |
| 200-Day Moving Average | 18.16 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -40.20M, while operating income came in at -40.20M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -40.20M |
| Pretax Income | -39.43M |
| Net Income | -39.43M |
| EBITDA | -40.20M |
| EBIT | -40.20M |
| Earnings Per Share (EPS) | -6.00 |
Balance Sheet
Total book value stands at -372.19M, with working capital of 12.87M providing operational flexibility.
| Cash & Cash Equivalents | 17.07M |
| Total Debt | N/A |
| Net Debt | -17.07M |
| Equity (Book Value) | -372.19M |
| Book Value Per Share | -56.60 |
| Working Capital | 12.87M |
Cash Flow
Annexin Pharmaceuticals AB produced -39.00M in operating cash flow over the past twelve months. After subtracting -129,000.00 in capital expenditures, free cash flow totaled -39.13M - equivalent to -5.95 per share.
| Operating Cash Flow | -39.00M |
| Capital Expenditures | -129,000.00 |
| Free Cash Flow | -39.13M |
| FCF Per Share | -5.95 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -12.73 |
| FCF Yield | -45.12 |
Stock Splits
Annexin Pharmaceuticals AB's most recent stock split took place on May 28, 2025 with a 100:1 split ratio.
| Last Split Date | 5/28/2025 |
| Split Ratio | 100:1 |
Scores
Annexin Pharmaceuticals AB posts an Altman Z-Score of -23.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -23.70 |